Myriad Genetics Inc. (MYGN) Tuesday reported third-quarter profit of $37.9 million or $0.46 per share, up from $29.6 million or $0.34 per share in same period last year.
On average, 17 analysts polled by Thomson Reuters expected the company to earn $0.40 per share for the quarter. Analysts' estimates typically exclude special items.
Revenues improved to $156.47 million from $129.78 million last year. Analysts expected revenues of $148.25 million.
Looking ahead, the company has raised its full-year 2013 earnings outlook to a range of $1.65 to $1.67 per share from the previous guidance of $1.55 to $1.58 per share.
Revenues are currently projected in a range of $595 million to $600 million, up from $575 million to $585 million, issued previously. Analysts currently expect the company to report full-year earnings of $1.58 per share on revenues of $583.50 million.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.